Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis.

Tests that can replace sputum smear microscopy have been identified as a top priority diagnostic need for tuberculosis by the World Health Organization. High-quality evidence on diagnostic accuracy for tests that may meet this need is an essential requirement to inform decisions about policy and scale-up. However, test accuracy studies are often of low and inconsistent quality and poorly reported, leading to uncertainty about true test performance. Here we provide guidance for the design of diagnostic test accuracy studies of sputum smear-replacement tests. Such studies should have a cross-sectional or cohort design, enrolling either a consecutive series or a random sample of patients who require evaluation for tuberculosis. Adults with respiratory symptoms are the target population. The reference standard should at a minimum be a single, automated, liquid culture, but additional cultures, follow-up, clinical case definition, and specific measures to understand discordant results should also be included. Inclusion of smear microscopy and Xpert MTB/RIF (or MTB/RIF Ultra) as comparators is critical to allow broader comparability and generalizability of results, because disease spectrum can vary between studies and affects relative test performance. Given the complex nature of sputum (the primary specimen type used for pulmonary TB), careful design and reporting of the specimen flow is essential. Test characteristics other than accuracy (such as feasibility, implementation considerations, and data on impact on patient, population and health systems outcomes) are also important aspects.

[1]  R. Colman,et al.  Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests. , 2019, Journal of Infectious Diseases.

[2]  P. Drain,et al.  Guidance for Studies Evaluating the Accuracy of Biomarker-Based Nonsputum Tests to Diagnose Tuberculosis. , 2019, The Journal of infectious diseases.

[3]  Claudia M Denkinger,et al.  Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles. , 2019, The Journal of infectious diseases.

[4]  D. Boyle,et al.  Which attributes within target product profiles for tuberculosis diagnostics are the most important to focus on? , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  M. Pai,et al.  Surrogate endpoints in global health research: still searching for killer apps and silver bullets? , 2018, BMJ Global Health.

[6]  M. Pai,et al.  Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress? , 2017, European Respiratory Journal.

[7]  L. Huang,et al.  Investigation of OMNIgene·SPUTUM performance in delayed tuberculosis testing by smear, culture, and Xpert MTB/RIF assays in Uganda , 2017, Journal of epidemiology and global health.

[8]  M. Pai,et al.  Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Dowdy,et al.  Higher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  Elie A Akl,et al.  GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. , 2016, Journal of clinical epidemiology.

[11]  Madhukar Pai,et al.  Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? , 2016, European Respiratory Journal.

[12]  S. Sharp,et al.  The spectrum effect in tests for risk prediction, screening, and diagnosis , 2016, British Medical Journal.

[13]  H. Jenkins,et al.  Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis , 2016, BMC Infectious Diseases.

[14]  G. Gore,et al.  Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies , 2016, PloS one.

[15]  D. Christopher,et al.  Impact of point-of-care implementation of Xpert® MTB/RIF: product vs. process innovation. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  D. Dowdy,et al.  The impact of novel tests for tuberculosis depends on the diagnostic cascade , 2014, European Respiratory Journal.

[17]  D. Dowdy,et al.  Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? , 2014, The Lancet. Infectious diseases.

[18]  J. Glynn,et al.  Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. , 2014, Bulletin of the World Health Organization.

[19]  N. Dendukuri,et al.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults , 2014, The Cochrane database of systematic reviews.

[20]  A. Ramsay,et al.  Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? , 2013, European Respiratory Journal.

[21]  Yemisi Takwoingi,et al.  Empirical Evidence of the Importance of Comparative Studies of Diagnostic Test Accuracy , 2013, Annals of Internal Medicine.

[22]  C. Dye,et al.  The impact of new tuberculosis diagnostics on transmission: why context matters. , 2012, Bulletin of the World Health Organization.

[23]  S. Dorman,et al.  Performance Characteristics of the Cepheid Xpert MTB/RIF Test in a Tuberculosis Prevalence Survey , 2012, PloS one.

[24]  R. Dietze,et al.  Evaluation of Processing Methods To Equitably Aliquot Sputa for Mycobacterial Testing , 2012, Journal of Clinical Microbiology.

[25]  Eduardo Gotuzzo,et al.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study , 2011, The Lancet.

[26]  Gordon H Guyatt,et al.  GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies , 2008, BMJ : British Medical Journal.

[27]  Dermot Maher,et al.  International standards for tuberculosis care. , 2006, The Lancet. Infectious diseases.

[28]  M. Perkins,et al.  Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. , 2006, The Lancet. Infectious diseases.

[29]  K Stepniewska,et al.  Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features , 2002, The Lancet.

[30]  Stephanie A. Mulherin,et al.  Spectrum Bias or Spectrum Effect? Subgroup Variation in Diagnostic Test Evaluation , 2002, Annals of Internal Medicine.

[31]  C. Gatsonis,et al.  Designing studies to ensure that estimates of test accuracy are transferable , 2002, BMJ : British Medical Journal.

[32]  E. Huhti,et al.  Tuberculosis of the cervical lymph nodes : a clinical, pathological and bacteriological study. , 1975, Tubercle.

[33]  L. Scharer,et al.  Isolation of tubercle bacilli from needle biopsy specimens of parietal pleura. , 1968, The American review of respiratory disease.

[34]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[35]  Herbert W. Berger,et al.  TUBERCULOUS pleurisy. , 1955, Lancet.

[36]  Soloff,et al.  [Tuberculous pericarditis]. , 1949, Arquivos brasileiros de medicina.